A Study to Assess the Short Term Efficacy of Intravenous Ibandronate (Bondronat) in Participants With Metastatic Bone Pain Due to Breast Cancer
This study will assess the short term efficacy of ibandronate (6 mg intravenous \[IV\]) in participants with breast cancer and malignant bone disease, with moderate to severe pain. All participants will receive an IV infusion of ibandronate on Days 1, 2, and 3, and pain response will be measured on Days 1-7. The anticipated time on study treatment is 3 days, and the target sample size is 182 individuals.
Pain; Bone Neoplasms; Neoplasm Metastasis
DRUG: Ibandronate
Percentage of participants with >=25% reduction in mean pain, up to Day 6|Percentage of participants with =<35% increase in mean analgesic consumption, up to Days 7
Change from Baseline in average pain score, Baseline (Days 0), 5, and 7|Analgesic consumption, up to Day 7|Pain response, up to Day 7|Time to pain response, up to Day 7
This study will assess the short term efficacy of ibandronate (6 mg intravenous \[IV\]) in participants with breast cancer and malignant bone disease, with moderate to severe pain. All participants will receive an IV infusion of ibandronate on Days 1, 2, and 3, and pain response will be measured on Days 1-7. The anticipated time on study treatment is 3 days, and the target sample size is 182 individuals.